# National Eye Institute (NEI): Phase 2 study closed enrollment, 55 enrolled (ABCA4 Retinopathy, Stargardt Disease)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | National Eye Institute (NEI) |
| Sponsor type | NIH |
| Study | Oral Metformin for Treatment of ABCA4 Retinopathy |
| NCT ID | NCT04545736 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | ABCA4 Retinopathy; Stargardt Disease; Retinal Dystrophy; Retinal Degeneration |
| Intervention types | drug |
| Target enrollment | 55 |
| Site countries | United States |
| Posted | 2020-09-11 |
| Planned start | 2020-11-23 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04545736). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.